Format

Send to

Choose Destination
Clin Rheumatol. 2006 Jul;25(4):596-7. Epub 2005 Oct 25.

Treatment of therapy-resistant sarcoidosis with adalimumab.

Author information

1
Avenida Dr. Oloriz sn, 18006, Granada, Spain. JLCALLEJA@telefonica.net

Abstract

A possible role of tumor necrosis factor alpha (TNFalpha) in the pathomechanism of sarcoidosis must be considered in the analysis of this disorder since elevated concentrations of this cytokine have been found. In addition, TNFalpha expression could be demonstrated in sarcoid granulomata [1]. It is well known that TNFalpha plays a crucial role in granulomatous inflammation, e.g., in mycobacterial diseases [2]. Therefore, TNFalpha blockade is a potential approach in the therapy for sarcoidosis. Up to now, various cases of therapy-resistant sarcoidosis treated with anti-TNFalpha (infliximab and etanercept) have been reported [3-8]. Here, we describe successful treatment using adalimumab, a human recombinant immunoglobulin (Ig) G1 anti-TNF monoclonal antibody [9].

PMID:
16247590
DOI:
10.1007/s10067-005-0037-9
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center